Updates

FISCHER MEDICAL VENTURES LIMITED Registered Office Address: Survey No. 480/2 AP Medtech Zone Nadupura Village, Pedagantyadu Mandal, Visakhapatnam, 530032 CIN: L86900AP1993PLC118162 Email: enquiry@fischermv.com | Website: www.fischermv.com | Contact 9080966548 September 16, 2026 To To BSE Limited National Stock Exchange of India Ltd. Corporate Relationship Department Exchange Plaza, 5tll floor 25th Floor, P J Towers Plot No. C/ 1, G Block, Dalal Street, Fort, Bandra-Kurla Complex Bandra (E), Mumbai – 400 001 Mumbai - 400 051 BSE Scrip Code: 524743 NSE Symbol: FISCHER Dear Sir/Madam, Subject: Chairman’s Letter to Shareholders We are pleased to enclose herewith the Chairman’s Letter to Shareholders, providing an overview of the Company’s business, key developments and its outlook. The letter is intended to keep shareholders informed of the Company’s progress and its ongoing initiatives. We request you to kindly take note of the same. Thanking you, Yours Truly, For FISCHER MEDICAL VENTURES LIMITED BALAJI GANDLA COMPANY SECRETARY & COMPLIANCE OFFICER Corporate Office: Level 8, Prestige Palladium Bayan, No. 129-140 Greams Road, Chennai, Tamil Nadu, 600006 CIN L86900AP1993PLC118162 Corporate Office : Level 8, Prestige Palladium Bayan, No. 129-140 Greams Road, Chennai, Tamil Nadu, 600006 Registered Office : No. 480/2 AP Medtech Zone, Nadupura Village, Pedagantyadu Mandal, Visakhapatnam, 530032 A letter to the shareholders of Fischer Medical Ventures Dear fellow shareholder, For most of the past year we chose to spend our time building machines, filing for approvals and winning projects rather than talking about them, and that choice has now produced results I want you to hear about directly from me. The quiet was not neglect; it was a year of work across offerings and across five regions. It was work, and this letter is the first of many in which I will show you what it built. Beyond imaging hardware, we have built a broader portfolio spanning point-of-care diagnostics, AI-enabled healthcare software and end-to-end solutions company along with AI-driven drug discovery (Nanyang Biologics, alongside NVIDIA, HPE and Equinix), and portable wound-care technology (an associate relationship with Nanomedic). We organise our business into three segments: Radiology, Preventive Healthcare, and Wellness Solutions. Radiology is our founding and largest segment today, and is detailed in full below, alongside an initial view of our Preventive Healthcare business and our Wellness Solutions concept and rollout plan. Preventive Healthcare, in particular is presented here at an early stage — an initial deployment example rather than a full segment review — and will be built out further as more information becomes available. Our Radiology business TMIV Imaging is built on a large, structurally under-served global market, a genuinely proprietary imaging technology platform with roots in university research, and a comprehensive product portfolio organised around three strategic pillars: Diagnostics, Screening, and Interventional Radiology. With our technology developed in-house, we believe we have built a platform that can scale beyond India and compete in global markets Pillar 1: Diagnostics Diagnostics is our broadest pillar, comprising comprehensive imaging systems for detailed clinical diagnosis — MRI, CT, X-ray and digital mammography — spanning both open and closed configurations across field strengths from 0.35T to 7T. Open MRI: AURIX (0.35T) is our flagship product and one of the most cost-effective, high- performance whole-body MRI systems on the market, eliminating the traditional barriers of helium dependence, extensive shielding, and high installation cost. Its six compelling advantages are enhanced patient comfort, lower total cost of ownership, flexible installation, expanded access to care, implant and device compatibility, and AI-enhanced workflow. In one children's hospital deployment, AURIX's open design and quiet operation supported a 42% decrease in general anesthesia cases for patients aged 4-12 (compared to standard 1.5T protocols) and a 95% satisfaction rate. AURA (0.7T) extends this open architecture with a full suite of advanced sequences — MR spectroscopy, diffusion tensor imaging, and perfusion imaging — typically reserved for high-field closed-bore systems. With these advancements, the image quality is comparable to, and in certain applications potentially better than, conventional 1.5T systems. These technology developments have also supported our expansion into global markets, including Italy, the United States, Africa, and South America, with an installation currently underway in South America. Closed MRI: MICA / MICA Smart (1.5T, 32- or 16-channel) offers a cost-effective, zero boil- off whole-body platform. QUIN (1.5T) is India's first helium-free 1.5T MRI system with a 70cm bore, cutting standard scan protocols from 45 minutes to 15 minutes, eliminating quench-pipe infrastructure, and requiring zero ongoing helium top-up. NEONA is a compact, FDA-approved neonatal MRI system designed for co-location within the NICU, incorporating an MR-compatible incubator; it reduces RF power deposition by 50-70%, cuts acoustic noise by 80%, and reduces imaging time by 50% — and is, on our disclosures, the first and only neonatal MRI system to win the Geneva Invention Award. Our next-generation premium platforms — NEXA (3T flagship), N- NEXA (3T helium-less) and NOVA (7T pre-clinical research) — are in development, with regulatory approvals in progress. CT: our CLARION range (32-, 64- and 128-slice, plus a wide-bore configuration) is built around a liquid metal bearing X-ray tube and Aegis detector system, delivering zero-wear tube longevity, high patient throughput, and consistent image quality; regulatory approval for the CLARION range is in progress. Digital Mammography and X-ray: Navigator DR CARE uses an amorphous silicon detector — the most widely used digital mammography detector type globally — while the Navigator 3000A adds integrated 3D tomosynthesis, improving cancer detection and reducing false positives relative to 2D mammography alone. Our VISION 500 and VISION 800 digital radiography-ready X-ray systems (40kW and 80kW generators respectively, dual-focus rotating anode tubes, 300kg patient capacity) underpin recent institutional wins, including our Rs 9.29 crore, 65-unit order from the Tamil Nadu state government referenced elsewhere in this document. Pillar 2: Screening Screening addresses a large and largely invisible public health need: approximately 1 in 20 people (around 5% of the population) may be living with an undetected brain aneurysm, and nearly 99% of cases go undetected until the critical moment when intervention could make a difference. After the incident, the chance of survival drops down to 1% if the patient is not attended to within the golden period. Preventive screening is the way forward in such a scenario where the chance of survival rises to 99% once detected in advance and attended to. Our screening portfolio is designed to bring rapid, targeted, and contrast-free imaging to preventive and emergency care settings, rather than requiring a full diagnostic scan. VEGA, which is a highly optimized low-field system, provides rapid, contrast-free, radiation-free vascular imaging for cerebrovascular assessment and stroke-risk evaluation. It uses enhanced field strength for faster acquisition, supporting acute stroke protocols in emergency departments. Pillar 3: Interventional Radiology Interventional Radiology brings real-time imaging directly into the operating theatre, enabling surgeons to make informed decisions during procedures with immediate imaging feedback — without moving the patient. This pillar anchors our most technologically advanced offering and our highest-profile recent commercial win. The Medharanya Suite (DRIS and DRIS+) is our intraoperative MRI platform, integrating augmented reality, AI/machine vision, Exoscop [Showing first 8,000 characters — download PDF for full document]